Clinical Pharmacology — MCQs

Clinical Pharmacology Indian Medical PG Practice Questions and MCQs

Question 41: Absolute contraindication of hormone replacement therapy is:

A. Fibroadenoma
B. Thrombosis (Correct Answer)
C. Fibrocystic disease
D. Hemorrhage

Explanation: ***Thrombosis*** - A history of **thrombosis** (e.g., DVT, pulmonary embolism) is an **absolute contraindication** to hormone replacement therapy (HRT) due to the increased risk of further **thromboembolic events**, as estrogen can promote coagulation [1], [2]. - HRT can increase the risk of **blood clot formation**, making it unsafe for individuals with a prior or current thrombotic condition [1]. *Fibroadenoma* - **Fibroadenomas** are **benign breast lumps** and are generally not considered an absolute contraindication for HRT. - While HRT can potentially cause some **breast density** changes, fibroadenomas do not typically preclude its use, though monitoring may be advised. *Fibrocystic disease* - **Fibrocystic breast disease** is a common **benign breast condition** characterized by lumpy, tender breasts, and it is **not an absolute contraindication** for HRT. - HRT might occasionally exacerbate breast tenderness in some women with fibrocystic changes, but it does not pose a severe health risk. *Hemorrhage* - Acute or uncontrolled **vaginal hemorrhage**, especially of undetermined etiology, is a contraindication to initiating HRT until the cause is identified and managed. - However, once the hemorrhage is controlled and its cause is determined not to be uterine cancer, previous hemorrhage itself is **not an absolute contraindication** to long-term HRT.

Question 42: 1 ml of 7.5% sodium bicarbonate provides:-

A. 0.5 meq bicarbonate
B. 0.9 meq bicarbonate (Correct Answer)
C. 1.5 meq bicarbonate
D. 1.1 meq bicarbonate

Explanation: ***0.9 meq bicarbonate*** - A 7.5% solution means 7.5 grams of sodium bicarbonate in 100 ml of solution. Thus, 1 ml contains **0.075 grams** (75 mg). - The molecular weight of sodium bicarbonate (NaHCO₃) is approximately **84 g/mol**. Since it is a monovalent ion, 1 mmol equals 1 mEq. Therefore, 75 mg is approximately **0.892 mEq**, which rounds to 0.9 mEq. *0.5 meq bicarbonate* - This value is significantly **lower** than the actual amount of bicarbonate contained in 1 ml of a 7.5% solution. - An error in calculation, such as an incorrect molecular weight or percentage conversion, would lead to this underestimation. *1.5 meq bicarbonate* - This value is **higher** than the actual amount of bicarbonate and would be closer to the concentration of a 12.5% solution or a significantly larger volume. - This suggests a **miscalculation** of the concentration or the amount present in 1 ml. *1.1 meq bicarbonate* - While closer than other incorrect options, this value is still an **overestimation**. - A slight error in the molecular weight used for calculation or in the initial mass conversion could lead to this result.

Question 43: What is the typical pH of Hartmann's solution?

A. Has a pH of approximately 5.5
B. Has a pH of approximately 7.4
C. Has a pH of approximately 6.5 (Correct Answer)
D. Has a pH of approximately 8.0
E. Has a pH of approximately 4.5

Explanation: Everything mentioned here pertains to pH values of biological fluids and intravenous solutions. ***Has a pH of approximately 6.5*** - Hartmann's solution, also known as **Lactated Ringer's solution**, typically has a pH of about **6.0 to 7.5**, with 6.5 being a good approximation. - Its slightly acidic nature, compared to physiological pH, is due to the presence of **lactic acid** which is later metabolized to bicarbonate. *Has a pH of approximately 5.5* - A pH of 5.5 is more **acidic** than typical Hartmann's solution and might be found in some other IV fluids like **0.9% normal saline**. - While Hartmann's is slightly acidic, it's generally not as acidic as 5.5. *Has a pH of approximately 7.4* - A pH of 7.4 is the **physiological pH of blood** [1]. - While Hartmann's solution is designed to be **isotonic** and help correct acidosis, its pH is not exactly 7.4 before infusion and metabolism. *Has a pH of approximately 8.0* - A pH of 8.0 is **alkaline** and significantly higher than the typical pH of Hartmann's solution. - Such a high pH would not be safe for routine intravenous administration. *Has a pH of approximately 4.5* - A pH of 4.5 is quite **acidic** and would be much more acidic than Hartmann's solution. - Infusion of a solution with such a low pH could lead to significant **acidosis** and other adverse effects in a patient.

Question 44: A 45-year-old man with type 2 diabetes develops tender hemorrhagic bullae on both legs after starting empagliflozin. Blood glucose is well-controlled. Most appropriate management is:

A. Add topical antibiotics
B. Switch to another SGLT2 inhibitor
C. Continue empagliflozin with wound care
D. Stop empagliflozin (Correct Answer)

Explanation: **Stop empagliflozin** * Empagliflozin, an **SGLT2 inhibitor**, is associated with an increased risk of **bullous pemphigoid**, especially in patients with diabetes. The presentation of **tender hemorrhagic bullae** strongly suggests this adverse drug reaction [1]. * Discontinuation of the offending drug is the **most appropriate initial management** to prevent further lesion development and allow for resolution [1]. *Add topical antibiotics* * Topical antibiotics might be used for **secondary infection** of the bullae, but they do not address the underlying cause of the condition, which is a drug-induced reaction. * Stopping the causative agent is paramount; treating symptoms alone without removing the trigger is insufficient. *Switch to another SGLT2 inhibitor* * Since the bullae are likely an **adverse effect** of the SGLT2 inhibitor class (specifically, association with bullous pemphigoid), switching to another drug within the same class (another SGLT2 inhibitor) would likely result in the recurrence or persistence of the adverse reaction. * Cross-reactivity is common among drugs within the same pharmacological class, especially for immune-mediated skin reactions. *Continue empagliflozin with wound care* * Continuing the drug that is causing a severe skin reaction like bullous pemphigoid is **contraindicated** and would lead to worsening of the condition and potential complications. * While wound care is important for managing the lesions, it does not address the underlying cause, and continuing the medication would prevent healing and increase patient morbidity.

Question 45: A 25-year-old woman with severe nodulocystic acne develops acute-onset fever, arthralgia, and osteolytic lesions while on isotretinoin. Most appropriate next step is:

A. Continue isotretinoin and add NSAIDs
B. Stop isotretinoin, start antibiotics (Correct Answer)
C. Decrease isotretinoin dose
D. Add oral steroids

Explanation: ***Stop isotretinoin, start antibiotics*** - The combination of **fever**, **arthralgia**, and **osteolytic lesions** in the context of isotretinoin use suggests the development of **isotretinoin-induced SAPHO syndrome** (Synovitis, Acne, Pustulosis, Hyperostosis, Osteitis). Although rare, it can mimic infection, and given the patient's acute symptoms and systemic involvement, stopping the potential offending agent (isotretinoin) and empirically treating with antibiotics for possible osteomyelitis is the safest initial step [1]. - While SAPHO syndrome is an autoimmune condition, initially ruling out and treating potential infection, especially with osteolytic lesions, is crucial before solely focusing on immunosuppression [2]. *Continue isotretinoin and add NSAIDs* - Continuing isotretinoin is inappropriate as it could be the **trigger** for the patient's systemic symptoms and osteolytic lesions. - While NSAIDs can alleviate arthralgia, they would not address the **underlying systemic inflammation** or potential infection suggested by the osteolytic lesions and fever. *Decrease isotretinoin dose* - Simply decreasing the dose might not be sufficient to halt the progression of an isotretinoin-induced inflammatory or autoimmune response like **SAPHO syndrome**. - The severity of symptoms with **fever** and **osteolytic lesions** warrants complete cessation of the suspected causative agent. *Add oral steroids* - While oral steroids might be considered for the inflammatory component of **SAPHO syndrome**, adding them without stopping the suspected trigger (isotretinoin) is not optimal. - Furthermore, if there's an underlying infection leading to the osteolytic lesions, steroids could worsen the clinical picture by **immunosuppression**.

Question 46: A patient with chronic sinusitis has nasal polyps, aspirin sensitivity, and asthma. Most appropriate treatment is:

A. Early polypectomy
B. Aspirin desensitization (Correct Answer)
C. Antibiotics
D. Topical steroids

Explanation: Aspirin desensitization - The combination of **nasal polyps**, **aspirin sensitivity**, and **asthma** is characteristic of **Aspirin-Exacerbated Respiratory Disease (AERD)**, also known as Samter's triad. - **Aspirin desensitization** is the most effective treatment for AERD as it addresses the underlying inflammatory pathway, leading to improved asthma control, reduced polyp recurrence, and decreased need for oral corticosteroids. *Early polypectomy* - While polypectomy can temporarily relieve symptoms by removing the polyps, it does not address the underlying inflammatory process of **AERD**. - Polyps in AERD patients have a **high recurrence rate** after surgical removal if the underlying aspirin sensitivity is not managed. *Antibiotics* - Antibiotics are used to treat **bacterial infections**, but they do not address the **chronic inflammatory condition** of AERD or the formation of nasal polyps. - Chronic sinusitis in AERD is often an inflammatory, not primarily infectious, process. *Topical steroids* - **Topical nasal steroids** can help manage chronic rhinosinusitis symptoms and may slow polyp growth but are generally insufficient as a sole treatment [1] for patients with established **AERD** and significant symptoms. - They provide **symptomatic relief** but do not modify the disease course in the same comprehensive way as aspirin desensitization.

Question 47: A patient with bronchial asthma develops osteoporosis. Most likely mechanism?

A. Calcium malabsorption
B. Inflammatory mediators
C. Physical inactivity
D. Chronic steroid use (Correct Answer)

Explanation: ***Chronic steroid use*** - **Glucocorticoids**, commonly used in the treatment of bronchial asthma, can directly inhibit **osteoblast activity** and promote **osteoclast activity**, leading to bone loss [1]. - They also reduce intestinal **calcium absorption** and increase **renal calcium excretion**, further disrupting calcium homeostasis and contributing to osteoporosis [1]. *Calcium malabsorption* - While **malabsorption syndromes** can cause osteoporosis, asthma itself does not directly lead to primary calcium malabsorption. - Steroids used in asthma treatment can *contribute* to reduced calcium absorption, but the primary mechanism of steroid-induced osteoporosis involves broader effects on bone metabolism, not solely malabsorption [1]. *Inflammatory mediators* - **Inflammatory mediators** associated with asthma may play a role in bone density loss, but their direct impact is less significant and less common than the effects of chronic steroid use [2]. - While chronic inflammation can indirectly affect bone remodeling, it is not the most likely or direct mechanism for osteoporosis in this clinical scenario compared to steroid exposure [1]. *Physical inactivity* - **Physical inactivity** can contribute to osteoporosis due to reduced mechanical loading on bones, but it is not a direct or primary cause specific to bronchial asthma [3]. - While severe asthma may lead to some activity limitation, the primary mechanism linking asthma treatment to osteoporosis is typically medication-related, rather than lifestyle factors alone.

Question 48: A patient on atorvastatin presents with myalgia; which test is recommended?

A. Liver function test
B. Blood urea nitrogen
C. Serum potassium
D. Creatine kinase (Correct Answer)

Explanation: ***Creatine kinase*** - **Myalgia** in a patient on **atorvastatin** raises concern for **statin-induced myopathy**, which can range from mild muscle aches to severe **rhabdomyolysis** [1]. - **Creatine kinase (CK)** levels are commonly used to assess muscle damage, with significantly elevated levels (e.g., >10 times normal) indicating rhabdomyolysis [1]. *Liver function test* - While atorvastatin can cause **hepatic dysfunction**, **myalgia** is not a primary symptom of liver injury [1]. - **Liver function tests (LFTs)** would be more relevant if the patient presented with jaundice, dark urine, or other signs of liver damage [1]. *Blood urea nitrogen* - **Blood urea nitrogen (BUN)** is a marker of **kidney function**, not directly related to muscle pain or statin-induced myopathy. - While severe **rhabdomyolysis** can lead to **acute kidney injury (AKI)**, BUN would be checked *after* CK levels indicate significant muscle breakdown. *Serum potassium* - **Serum potassium** levels are important for **cardiac and muscle function**, but myalgia itself does not directly indicate a potassium imbalance. - **Hyperkalemia** can occur secondary to severe **rhabdomyolysis** due to the release of intracellular potassium from damaged muscle cells, but CK is the initial diagnostic test for muscle injury.

Question 49: A 50-year-old male with diabetes presents with severe burning pain in his feet. Medications have been ineffective. What is the most appropriate next step in management?

A. Prescribe opioid analgesics
B. Prescribe corticosteroids
C. Trial of pregabalin (Correct Answer)
D. Refer for physical therapy

Explanation: ***Trial of pregabalin*** - **Pregabalin**, a gamma-aminobutyric acid (GABA) analog, is a first-line treatment for **diabetic neuropathic pain** due to its efficacy in modulating neurotransmitter release [2]. - Given that previous medications have been ineffective for **severe burning pain** [1] in diabetic neuropathy, exploring other pharmacological options like pregabalin is the most appropriate next step [2]. *Prescribe opioid analgesics* - **Opioid analgesics** are generally reserved for neuropathic pain that is refractory to other treatments due to concerns about tolerance, dependence, and significant side effects [1]. - They are not considered a first-line or early second-line treatment for **diabetic neuropathy**, especially when other agents like pregabalin have not yet been trialed [2]. *Prescribe corticosteroids* - **Corticosteroids** are potent anti-inflammatory agents but are not indicated for the chronic management of **diabetic neuropathic pain**, which is primarily a nerve damage issue rather than an inflammatory one. - Long-term steroid use carries significant risks and would likely worsen diabetes control, making it an inappropriate choice. *Refer for physical therapy* - **Physical therapy** can be beneficial for managing some aspects of diabetic neuropathy, such as improving balance or muscle strength, but it is unlikely to directly alleviate severe burning neuropathic pain as a primary monotherapy. - While a valuable adjunctive treatment, it is not the most appropriate initial next step for directly addressing severe pain symptoms when pharmacological options are still available [2].

Question 50: A patient presents with a temperature of 40°C and flushed skin. Which of the following interventions is most appropriate to lower the body temperature?

A. Applying a heating blanket
B. Increasing room temperature
C. Providing warm fluids
D. Administering antipyretics (Correct Answer)

Explanation: ***Administering antipyretics*** - **Antipyretics** such as acetaminophen or ibuprofen directly act on the **hypothalamus** to reset the body's thermoregulatory set point, promoting heat loss and reducing fever [1]. - They are the most appropriate first-line intervention for **febrile patients** with a high temperature, as they address the underlying mechanism of fever [3]. *Applying a heating blanket* - This intervention would **increase** the patient's body temperature, which is the opposite of the desired effect for a patient with a fever of 40°C. - **Heating blankets** are used for hypothermia, not hyperthermia. *Increasing room temperature* - Raising the room temperature would make it harder for the patient's body to dissipate heat, potentially leading to a **further increase** in body temperature [1]. - A cooler environment promotes heat loss through **convection** and **radiation** [1], [4]. *Providing warm fluids* - While hydration is important, providing **warm fluids** would add heat to the patient's body, which is counterproductive in this situation [2]. - **Cool or room-temperature fluids** are generally preferred for hydration during fever to avoid contributing to the elevated body temperature [2].

Practice by Chapter

Pharmacokinetics and Pharmacodynamics

Practice Questions

Drug Metabolism and Excretion

Practice Questions

Adverse Drug Reactions and Interactions

Practice Questions

Therapeutic Drug Monitoring

Practice Questions

Pharmacogenomics and Precision Medicine

Practice Questions

Drug Development and Clinical Trials

Practice Questions

Rational Prescribing and Deprescribing

Practice Questions

Medication Adherence Strategies

Practice Questions

Special Populations (Pediatric, Geriatric, Pregnancy)

Practice Questions

Pharmacovigilance

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free